ILF2 and prostate adenocarcinoma: In multiple myeloma, increased ILF2 is associated with therapeutic resistance mediated through DNA repair pathways [40], and it is interesting to note that increased expression of NUSAP1 is associated with DNA repair pathways in the PRAD data in our study and others [3].